Danish drugmaker LEO Pharma has won US approval for Taclonex, a topical treatment for psoriasis that will be sold in the USA by partner Warner Chilcott.
Taclonex is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064%, and has been cleared for the treatment of psoriasis in adults. The product is already sold outside the USA as Dovobet or Daivobet. Warner Chilcott said it expects to launch Taclonex in the first half of 2006.
Meanwhile, Warner Chilcott acquired US marketing rights to LEO’s Dovonex (calcipotriene 0.005%), the leading non-steroidal topical treatment for psoriasis, from Bristol-Myers Squibb Company as of January 1.
